The healthcare company received European approval for a new prefilled syringe presentation of its Shingrix vaccine, simplifying administration for healthcare professionals.
The pharmaceutical company announced positive phase 3 trial results for its investigational chronic hepatitis B treatment, bepirovirsen, which met primary endpoints and could become a transformative therapy for the disease.
The healthcare company has received approval in Japan for its new biologic treatment for severe respiratory conditions.
The pharmaceutical company has announced changes to director and PDMR shareholdings.
The healthcare company announced that its respiratory drug Nucala has been approved in China for use in adults with chronic obstructive pulmonary disease.
The healthcare company's non-executive directors have purchased additional shares in the business.
The pharmaceutical company has entered an agreement with the U.S. government to lower the cost of its respiratory medicines and expand access for American patients.
The healthcare company has received FDA approval for its new severe asthma treatment, Exdensur, which offers twice-yearly dosing.
The healthcare company has received UK approval for its new respiratory drug Exdensur, which can be used to treat asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
The pharmaceutical company has received a positive recommendation from the CHMP for its Nucala drug to be used as a treatment for chronic obstructive pulmonary disease (COPD).